Clinical trials: tuberculosis
Tuberculosis, Pulmonary
Azacytidine During Anti-tuberculosis Therapy
Tuberculosis has been shown to make immune genes inaccessible and slows immune response The purpose of this research is to see if if azacitidine is safe and can return the ability of the body to resist tuberculosis (TB), a…
- Trial name
- AZA (NCT03941496)
- Testing
- Azacitidine Injection
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Andrew Dinardo
Tuberculosis
A Trial of Isoniazid for the Reversion of Interferon Gamma ELISPOT in Tuberculosis (TB) Case Contacts
There are new TB vaccines already developed that need to be tried in humans to assess their efficacy. The researchers had previously shown that production of interferon gamma by T cells in response to TB antigens is a more…
- Trial name
- IRS (NCT00130325)
- Testing
- Isoniazid
- Where
- The Gambia
- Volunteers
- 214 people, healthy volunteers welcome
- Sponsor
- Medical Research Council Unit, The Gambia
Tuberculosis
Study Evaluating Aerosol and Intradermal Administration of a Candidate Tuberculosis (TB) Vaccine, MVA85A, as a Way to Increase Immune Response and Avoid Anti-vector Immunity
Boost vaccinations sometimes have no effect because the body has got used to the vaccine and no longer reacts to it. We are therefore investigating whether vaccinating with aerosolised MVA85A (a candidate tuberculosis vaccine)…
- Trial name
- NCT01954563
- Testing
- MVA85A
- Where
- United Kingdom
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Multi-drug Resistant Tuberculosis
Case Control Study of Vitamin D Status and Adult Multidrug-resistant Pulmonary Tuberculosis in Maharashtra, India
India has the highest incidence of and mortality from multi-drug resistant tuberculosis (MDR-TB) globally. Vitamin D status may be an important determinant of MDR-TB infection and treatment outcomes; however, observational…
- Trial name
- NCT04342598
- Testing
- Serum Vitamin D
- Where
- India
- Volunteers
- 352 people, healthy volunteers welcome
- Sponsor
- Harvard School of Public Health (HSPH)
Latent Tuberculosis
BCG Re-vaccination for Primary Tuberculosis Prophylaxis in the Prison Population
In the last decade, the incidence of tuberculosis (TB) has declined in much of the world, but has increased in Central and South America.
- Trial name
- PPT-BCG (NCT05541952)
- Testing
- BCG
- Where
- Brazil
- Volunteers
- healthy volunteers welcome
- Sponsor
- Federal University of Mato Grosso
Tuberculosis
A Study to Evaluate Safety and Immunogenicity of AERAS-402 Administered in HIV-negative, BCG-vaccinated, QFT (+) and (-) Adults Without Evidence of TB
The available live tuberculosis vaccine Bacillus Calmette-Guérin (BCG) provides incomplete protection against pulmonary tuberculosis.
- Trial name
- C-012-402 (NCT02430506)
- Testing
- AERAS-402
- Where
- Kenya
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Aeras
Latent Tuberculosis Infection
Clinical Trial of Mica
This study used a randomized, open, blank control design. A total of 6800 patients over 15 years old with latent mycobacterium tuberculosis infection who met the inclusion criteria but did not meet the exclusion criteria were…
- Trial name
- NCT05680415
- Testing
- Mycobacterium Vaccae for Injection
- Where
- 2 sites in China
- Volunteers
- 6,800 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Latent Tuberculosis Infection
Screening for Latent Tuberculosis in Healthcare Workers With Quantiferon-Gold Assay: A Cost-Effectiveness Analysis
The ministry of health in Israel requires all health-care workers to undergo screening for latent Tuberculosis infection (LTBI) prior to starting work. This is based on the Mantoux skin test, which is notoriously unreliable.
- Trial name
- NCT00449345
- Testing
- Blood test for Quantiferon-GOLD assay
- Where
- Israel
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Assuta Hospital Systems
Pulmonary TB
Phase 1 Clinical Trial of Single-Vial ID93 + GLA-SE in Healthy Adults
This is a phase 1, double-blind, randomized clinical trial to evaluate the safety, tolerability, and immunogenicity of single-vial lyophilized ID93 + GLA-SE compared to the two-vial presentation consisting of lyophilized ID93 and…
- Trial name
- NCT03722472
- Testing
- ID93 + GLA-SE
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Access to Advanced Health Institute (AAHI)
Tuberculosis
A Phase I Randomized Placebo-Controlled, Double-Blind Study to Evaluate Safety and Immunogenicity of AERAS-404 Administered as Different Amounts of Antigen and Adjuvant Combinations in HIV-Negative BCG-Vaccinated Adults Without Evidence of Tuberculosis Infection
Phase I, randomized, double blinded, Placebo-controlled, immunogenicity and dose-range finding study of AERAS-404 in Bacille Calmette-Guerin (BCG) healthy adult male and sterile females.
- Trial name
- NCT02066428
- Testing
- AERAS-404
- Where
- Sweden
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Aeras
Obesity, Leprosy
Effect of Weight and/or Obesity on Dapsone Drug Concentrations
This study will find how weight affects the dosing of a drug called dapsone. Currently, the amount of dapsone a patient receives is the same regardless of the patient's weight.
- Conditions
- Obesity, Leprosy, Tuberculosis
- Trial name
- NCT01165840
- Testing
- Dapsone
- Where
- United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Texas Tech University Health Sciences Center
Tuberculosis, Pulmonary, Rifampicin Resistant Tuberculosis
GeneXpert Performance Evaluation for Linkage to Tuberculosis Care
The investigators' overall objective is to assess the effectiveness, implementation and costs of a streamlined TB diagnostic evaluation strategy based around rapid, onsite molecular testing.
- Trial name
- XPEL-TB (NCT03044158)
- Testing
- GeneXpert I, Process re-design, Performance Feedback
- Where
- 20 sites in Uganda
- Volunteers
- 10,644 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Healthy Volunteers
Impact of Weekly Administration of Rifapentine and Isoniazid on Steady State Pharmacokinetics of Tenofovir Alafenamide in Healthy Volunteers (YODA)
Background: Human immunodeficiency virus (HIV) is treated with antiretroviral drugs. Many people with HIV also have the lung infection tuberculosis (TB). Most TB treatments are complicated.
- Trial name
- NCT03510468
- Testing
- Tenofovir alafenamide, Rifapentine, Isoniazid (INH)
- Where
- United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- National Institutes of Health Clinical Center (CC)
Tuberculosis
Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in Healthy Infants
This purpose of the study is to assess the safety and immunogenicity of a GSK Biologicals' candidate tuberculosis vaccine (692342) when administered concomitantly with or after the Expanded Programme of Immunisation vaccines…
- Trial name
- NCT01098474
- Testing
- GSK's investigational vaccine 692342, Tritanrix™ HB+Hib, Prevnar™
- Where
- The Gambia
- Volunteers
- 301 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Tuberculosis, Drug Induced Liver Injury
Efficacy of N-acetylcysteine to Prevent Anti-tuberculosis Drug-induced Liver Injury: A Randomized Controlled Trial
To determine the efficacy of NAC to prevent clinically significant anti-TB drugs induced liver injury (AT-DILI).
- Conditions
- Tuberculosis, Drug Induced Liver Injury, Hepatitis
- Trial name
- NCT05738681
- Testing
- N acetyl cysteine
- Where
- Thailand
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Mahidol University
Tuberculosis
A Step Forward for Unraveling the Immune Mechanisms and Tools for Tuberculosis Spectrum Management
Tuberculosis (TB) is a significant infectious disease worldwide, with millions of people infected and major impact on mortality and public health.
- Trial name
- TB-SPECTRUM (NCT07735754)
- Volunteers
- 940 people, healthy volunteers welcome
- Sponsor
- Irene Latorre Rueda
Healthy
First-in-Human Trial of the Novel Tuberculosis Vaccine Candidate, H107e/CAF®10b
Tuberculosis (TB) is an infection caused by bacteria passed from one person to another through the air when an infected person for instance coughs, speaks, or sneezes.
- Trial name
- nTB-01 (NCT06050356)
- Testing
- H107e, CAF®10b, H107e/CAF®10b - low adjuvant dose
- Where
- South Africa
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Statens Serum Institut
Tuberculosis, Tuberculosis, Pulmonary
A Phase 1 Study to Evaluate Safety, Tolerability, PK, and PK Interactions of TBA-7371
The primary objective of the study is to evaluate the safety and tolerability of single and multiple doses of TBA-7371 in healthy subjects
- Trial name
- NCT03199339
- Testing
- TBA-7371
- Where
- United States
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Global Alliance for TB Drug Development
Compliance, Patient
Treatment of Latent Tuberculosis in Socially Marginalised Citizens
An open-label, randomised controlled trial comparing compliance to treatment for latent tuberculosis infection in socially marginalised citizens.
- Trial name
- DOT-LTBI (NCT03266991)
- Testing
- Rifapentine, Isoniazid
- Where
- 2 sites in Denmark
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Aarhus University Hospital
Tuberculosis, Diagnostics
Rapid Research in Diagnostics Development for TB Network (R2D2 Kids) and Assessing Diagnostics At POC for TB in Children (ADAPT for Kids)
Every year there are an estimated 230,000 childhood deaths from TB. There is an urgent need for novel tests for TB diagnosis in children under 15 years.
- Conditions
- Tuberculosis, Diagnostics, Global Health
- Trial name
- NCT05989802
- Testing
- Oral swab molecular testing, Automated Cough Sound Analysis, Automated Lung Sound Analysis
- Where
- 3 sites in Mozambique, South Africa and 1 more
- Volunteers
- 2,100 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco